One specific immunotherapy strategy is the blockade of CCL2/MCP-1 (monocyte chemoattractant protein-1), an elevated cytokine during CRC progression which recruits monocytes to the tumor microenvironment [9]. The gene discussed is CCL2; the disease is neoplasm.